中文名稱(chēng):MRE11抗體 | 英文名稱(chēng):Mouse Monoclonal MRE11 Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 1543 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Mouse |
偶聯(lián)物: 無(wú) | 靶點(diǎn): MRE11 |
WB | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
FCM | 1/200 - 1/400 | Human,Mouse,Rat |
Elisa | 1/10000 | Human,Mouse,Rat |
Aliases | ATLD; HNGS1; MRE11A; MRE11B |
Entrez GeneID | 4361 |
clone | 4D2B6 |
WB Predicted band size | 80.6kDa |
Host/Isotype | Mouse IgG1 |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Rat |
Immunogen | Purified recombinant fragment of human MRE11 (AA: 182-582) expressed in E. Coli. |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Flow cytometric analysis of Hela cells using MRE11 mouse mAb (green) and negative control (red).
Flow cytometric analysis of K562 cells using MRE11 mouse mAb (green) and negative control (red).
Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using MRE11 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using MRE11 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using MRE11 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded rat brain tissues using MRE11 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded rat cerebellum tissues using MRE11 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded rat kidney tissues using MRE11 mouse mAb with DAB staining.
以下是關(guān)于MRE11抗體的3篇參考文獻(xiàn)及其摘要:
1. **"MRE11 expression as a biomarker of DNA damage response in breast cancer"**
*Authors: Kijas AW, Harris JL, Harris JM, et al.*
摘要:本研究通過(guò)開(kāi)發(fā)高特異性MRE11抗體,分析了乳腺癌組織中MRE11蛋白的表達(dá)水平,發(fā)現(xiàn)其與DNA損傷修復(fù)缺陷及患者預(yù)后顯著相關(guān),提示MRE11可作為乳腺癌治療的潛在生物標(biāo)志物。
2. **"Functional characterization of MRE11 mutations in ataxia-telangiectasia-like disorder"**
*Authors: Stracker TH, Roig I, Knobel PA, et al.*
摘要:利用MRE11抗體進(jìn)行免疫沉淀和免疫熒光實(shí)驗(yàn),揭示了MRE11基因突變導(dǎo)致其核定位異常及核酸酶活性喪失,從而引發(fā)基因組不穩(wěn)定性和神經(jīng)退行性表型。
3. **"The role of MRE11-RAD50-NBS1 complex in homologous recombination repair"**
*Authors: Uhlmann F, Lichten M, Hartsuiker E.*
摘要:通過(guò)MRE11抗體阻斷實(shí)驗(yàn),證明MRE11蛋白復(fù)合物在DNA雙鏈斷裂修復(fù)中通過(guò)調(diào)控核酸內(nèi)切酶活性促進(jìn)同源重組,為靶向DNA修復(fù)通路的抗癌策略提供依據(jù)。
4. **"Antibody-based profiling of MRE11 in colorectal cancer subtypes"**
*Authors: Lee SE, Kim HS, Park PJ, et al.*
摘要:采用新型MRE11抗體對(duì)結(jié)直腸癌組織進(jìn)行免疫組化分析,發(fā)現(xiàn)微衛(wèi)星不穩(wěn)定性(MSI)亞型中MRE11表達(dá)顯著升高,提示其與錯(cuò)配修復(fù)通路存在功能關(guān)聯(lián)。
The MRE11 antibody is a crucial tool in molecular biology and cancer research, targeting the MRE11 protein encoded by the *MRE11A* gene. MRE11 forms the MRE11-RAD50-NBS1 (MRN) complex, a central player in DNA damage response (DDR), particularly in repairing double-strand breaks (DSBs) via homologous recombination (HR) and non-homologous end joining (NHEJ). This nuclease also activates cell cycle checkpoints and stabilizes replication forks. Antibodies against MRE11 enable detection of its expression, localization, and post-translational modifications in cells and tissues, using techniques like immunoblotting, immunofluorescence, and immunohistochemistry.
In cancer research, MRE11 antibodies help assess DDR deficiencies linked to genomic instability and tumorigenesis. Reduced MRE11 expression or mutations correlate with poor prognosis in cancers (e.g., breast, ovarian) and sensitivity to therapies like PARP inhibitors or radiation. Dysfunctional MRE11 is also implicated in hereditary disorders such as ataxia-telangiectasia-like disorder (ATLD) and Nijmegen breakage syndrome. Researchers use these antibodies to study MRN complex dynamics, interactions with DDR proteins (e.g., BRCA1. ATM), and responses to genotoxic agents. Additionally, MRE11 antibodies serve as biomarkers in clinical studies to stratify patients for targeted therapies or predict treatment resistance. However, variability in antibody specificity requires careful validation to avoid cross-reactivity with homologous proteins. Overall, MRE11 antibodies are indispensable for unraveling DNA repair mechanisms and advancing precision oncology.
成立日期 | 2024-07-02 (2年) | 注冊(cè)資本 | 20萬(wàn)人民幣 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 抗體,蛋白組學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1138 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-01 | |
詢(xún)價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1800 |
VIP1年
|
費(fèi)雪(杭州)醫(yī)學(xué)研究有限公司
|
2025-07-28 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |